Table 1.

Effects of intravesical infusion of HC-067047 in WT and NGF-OE mice on bladder pressure and compliance

	Bladder Pressure, cmH2O
Experimental Groups	Baseline	Threshold	Maximum	Bladder Compliance, µL/cmH2O
WT + vehicle	18.4 ± 2.3	22.3 ± 1.7	32.4 ± 1.4	28.8 ± 3.2
NGF-OE + vehicle	19.1 ± 1.5	21.5 ± 1.2	31.5 ± 1.8	13.3 ± 5.6*
WT + HC-067047 (1 µM)	18.3 ± 1.4	22.4 ± 1.6	30.3 ± 1.6	33.8 ± 4.8
NGF-OE + HC-067047 (1 µM)	20.7 ± 1.2	23.2 ± 1.4	30.1 ± 1.5	30.7 ± 3.4*

Values are means ± SE; n = 8 for each group. Bladder pressure (baseline, threshold, and maximum) and bladder compliance were measured using conscious cystometry in littermate wild-type (WT; n = 8) and transgenic mice with chronic urothelial overexpression of nerve growth factor (NGF-OE; n = 8) before and after intravesical instillation of HC-067047 (1 µM). NGF-OE and littermate WT mice exhibited similar bladder pressures. Intravesical instillation of HC-067047 (1 µM) was without effect on any bladder pressure measured in littermate WT or NGF-OE mice. Urinary bladder compliance was significantly reduced in NGF-OE mice compared with WT mice. Intravesical infusion of HC-067047 (1 µM) significantly increased bladder compliance in NGF-OE mice but was without effect on bladder compliance in WT mice.

^*P ≤ 0.01.